Preclinical drug development: a step-by-step guide from target to proof of concept
Introduction: what preclinical drug development covers and why it matters
Preclinical drug development covers the research conducted before a therapy can move into first-in-human studies. It starts with the identification and validation of a biological target and continues through assay development, lead selection, pharmacology, safety testing, and proof-of-concept studies. Each stage builds the evidence needed to judge whether the therapeutic concept is sufficiently supported to advance beyond laboratory research. Together, these activities generate the evidence needed to support a clear go/no-go decision and, where applicable, an Investigational New Drug filing.
The quality of the resulting data package affects more than regulatory readiness. It also shapes the credibility of the development program, the strength of investor discussions, and the confidence placed in future clinical plans. Weak experimental design or poorly connected datasets can create uncertainty at later stages, even when the underlying science is promising.
A practical understanding starts with a precise definition of what preclinical development includes.
What is preclinical drug development?
A practical answer to what is preclinical drug development starts with its role in the wider discovery process. At this stage, candidate molecules, biologics, and other therapeutic approaches are examined in laboratory models and animal systems before any testing in humans begins. The work usually brings together target identification and validation, assay development, compound profiling, pharmacology, and proof-of-concept studies. Each activity contributes a different part of the evidence needed to assess whether a therapeutic idea is scientifically sound and suitable for further development.
Within early-stage biotech, preclinical drug development is often used in a narrower, more practical sense. It refers to the biology-driven program that builds enough evidence to support investment discussions, development planning, and an informed decision on whether a candidate should advance. The aim is not simply to produce more data, but to establish a coherent case around mechanism, activity, and translational potential.
That process begins with selecting and validating the right biological target.
Step 1 - Target identification and validation
Before a program moves forward, the proposed target must be tied to the disease by more than correlation. The central question is whether changing its activity can alter the disease process in a therapeutically useful way. For that reason, a preclinical target needs evidence of both biological relevance and practical modulatability.
Omics studies often provide the starting signal by identifying genes, proteins, or pathways associated with a disease phenotype. CRISPR and RNAi can help test whether changing target activity has a measurable effect on the disease phenotype. Depending on the biological question, the target may be increased, reduced, or removed. Biochemical and cellular experiments then provide a closer look at whether the observed response is consistent with the proposed mechanism.
Target selection and validation methods are covered in a separate blog.
With the target case established, attention shifts to building assays that can measure its biology reliably and that allow for compound SAR (structure activity relation) testing.
Step 2 - Assay development
Once the target has been validated, the next task is to build reliable tools for measuring how and which compounds or other interventions affect its biology. Assay development in drug discovery is therefore a foundational investment, not a technical formality. Weak assays can distort potency estimates, hide relevant effects, and undermine every dataset produced later in the program.
Biochemical assays measure activity in a controlled molecular system, while cell-based assays examine responses in a more biologically relevant setting. MSD and other immunoassay platforms are often used to quantify proteins, biomarkers, or pathway changes. The appropriate choice depends on the scientific question, the development stage, and the decision the data must support.
Fit-for-purpose development means that assay sensitivity, reproducibility, controls, and operating range are matched to that intended use. As a result, assay quality directly affects compound profiling, pharmacology, candidate selection, and proof-of-concept work.
Target engagement evidence is also needed to show that the candidate reaches and binds to the intended target under relevant conditions. Without that link, downstream pharmacology may be difficult to interpret, since the observed effect could result from activity elsewhere in the system rather than from the expected mechanism.
Cell-based assays for drug discovery are covered in a separate blog.
MSD assay development is explained in a dedicated resource.
Assay development services are available through Discovery Studio.
With dependable assays in place, the program can move into systematic compound profiling.
Step 3 - Compound profiling and pharmacology
After assay development comes the question of which compounds merit further investment. The first hits emerging from a screen are rarely final candidates. Most require substantial optimization before they can support a development programme. Researchers modify and retest related compounds to understand how structural changes affect activity and selectivity. Structure-activity relationship analysis guides this work, helping teams identify which chemical features improve the profile and which introduce liabilities. Compound selection and profiling run in parallel. The profiling data determines which candidates are strong enough to move into proof-of-concept studies and beyond. A weak profile at this stage is not a dead end. It is information that feeds back into the next round of design.
Compound profiling shows whether a candidate is sufficiently characterized to move into a proof-of-concept study. Potency provides an early indication of activity, although strength against the intended target does not settle the decision on its own. Selectivity also matters because activity against related proteins or pathways can complicate data interpretation and raise early safety concerns.
Mechanism-of-action studies form an important part of preclinical validation because they test whether the observed biological response can be traced back to the intended target interaction. In parallel, ADME profiling examines absorption, distribution, metabolism, and excretion to clarify how the compound behaves once it enters a biological system. The resulting data helps define likely exposure, an appropriate dosing schedule, and the experimental model best suited to the program. Early safety assessment is carried out at the same stage to identify concerns such as cytotoxicity, off-target activity, or poor tolerability before the candidate moves into larger studies.
These findings shape the proof-of-concept plan that follows. A compound with limited exposure may require a different route of administration, while a short half-life may affect dosing frequency. Selectivity concerns can change endpoint selection or lead to additional controls. Likewise, the expected mechanism should guide the choice of biomarkers and the timing of sample collection.
In early stage drug development, the profiling phase should end with defined go/no-go criteria. A candidate may proceed when it shows sufficient potency, acceptable selectivity, evidence of target engagement, workable exposure, and no immediate safety barrier at relevant concentrations. Failure to meet these thresholds usually calls for compound optimization, selection of an alternative candidate, or reassessment of the program. Proof of concept should not be used to solve unresolved profiling questions.
Once a candidate meets the agreed profile, the program can move into a focused proof-of-concept study.
Step 4 - Proof of concept
Proof of concept, or PoC, demonstrates that the therapeutic hypothesis holds in a biologically relevant model system and provides an important translational step between preclinical research and clinical development. By linking biological findings with a measurable therapeutic effect, PoC studies help determine whether a candidate has sufficient evidence to justify further development. It is the natural endpoint of preclinical drug development because it brings together the evidence generated during target validation, assay development, compound profiling, pharmacology, and early safety assessment.
At this stage, the central question is whether the candidate produces the expected biological effect in a system that reflects the disease context closely enough to support a development decision. A positive result does not remove every remaining uncertainty, but it can provide a clear basis for further translational work, additional optimization, or clinical planning.
Proof of concept studies in biotechnology are covered in a separate blog.
From preclinical to clinical: the translational bridge
A positive preclinical proof of concept is not the end of development. It is the point at which a program may be considered ready for the work needed before clinical testing. IND-enabling studies then address pharmacology, toxicology, manufacturing, and regulatory requirements in enough depth to support first-in-human testing. Once that package is complete, Phase I studies can examine safety, tolerability, pharmacokinetics, and early biological activity in humans.
Preclinical to clinical translation depends on how well the earlier data support the proposed mechanism, dose rationale, biomarker strategy, and patient selection plan. Gaps in target engagement, exposure, or model relevance can weaken the clinical case, even when the preclinical findings appear positive. By contrast, a coherent data package gives clinical teams, regulators, and investors a clearer basis for judging development risk.
Clinical proof of concept comes later, when the therapeutic hypothesis is tested in patients rather than preclinical models.
Translational research in drug development is covered in a separate blog.
At this point, external scientific and strategic support may help the program prepare for its next development milestone.
When to bring in external biology support
External biology support adds most value when internal gaps begin to affect timing, data quality, or decision confidence. In preclinical drug development, those gaps often appear when a team lacks the assay infrastructure, disease-model expertise, or operational capacity needed to keep experiments moving. External support can prevent delays without requiring the company to build every capability in-house.
Independent validation is another trigger. Reproducing key findings outside the originating team can strengthen confidence in target biology, assay performance, and model relevance before studies progress. Specialist support is also valuable when the program depends on omics platforms, complex assay formats, or patient-derived models that require established methods and experienced interpretation.
The differences among these support models are covered in a separate blogs on biotech accelerator vs incubator.
Unlike a transactional CRO model, an accelerator can connect experimental execution with scientific strategy, milestone planning, and investor-facing evidence needs. Discovery Studio organizes this integrated support through our service tracks.
Search all newsposts
Popular Posts
Tags
Get in touch with us
Frequently asked questions about preclinical drug development
What is preclinical drug development?
Before a potential therapy reaches human studies, a substantial body of laboratory evidence must be generated. Preclinical drug development covers that phase, from confirming that a biological target is relevant to disease through to producing proof-of-concept evidence in suitable experimental models. This work helps determine whether a candidate has enough scientific support, biological activity, and early safety information to justify further development.
What are the stages of preclinical drug development?
Target identification and validation come first. This stage asks whether the biology actually supports intervention. Once that is established, assay development provides the tools to measure activity reliably. Compound profiling follows, characterizing potency, selectivity, and early drug-like behavior. Proof-of-concept testing then asks the critical question: can the candidate produce a meaningful effect in a relevant model? Each stage addresses a different type of uncertainty. Together, these preclinical drug development steps reduce risk around the target, the molecule, and the experimental evidence.
How long does preclinical drug development take?
A preclinical program often takes between one and three years. The exact duration reflects the therapeutic modality, the complexity of the biology, and whether suitable assays already exist. Time also increases when new disease models must be developed or when investors and regulators require a broader evidence package before the program can advance.
What data is generated during preclinical drug development?
Evidence accumulates across several connected areas during preclinical drug development. Target validation data shows whether the chosen biology is linked to disease, while assay performance results confirm that experimental methods are reliable. Compound studies establish potency and selectivity, and ADME work describes how the candidate is absorbed, distributed, metabolized, and eliminated. The broader preclinical research drug discovery effort then uses proof-of-concept results to judge whether these findings produce a meaningful effect in a relevant model.
What is the difference between preclinical and clinical drug development?
The dividing line is the start of human testing. Before that point, researchers study a candidate in laboratory systems, cell models, and animals to understand activity, exposure, and safety. Clinical development begins only after regulatory authorization. Early trials assess tolerability, dose selection, pharmacokinetics, and initial safety, whereas later studies investigate whether the treatment delivers a therapeutic benefit in the intended patient population.
What is an IND and when does it come after preclinical development?
Before a drug candidate can enter clinical trials in the United States, the sponsor submits an Investigational New Drug application to the FDA. The IND presents the pharmacology and toxicology findings, describes manufacturing and quality controls, and sets out the proposed clinical study. Filing usually follows proof-of-concept work and the required IND-enabling studies, once the program has enough evidence to support a reasonable starting dose and a defensible human trial plan.
When should a biotech company bring in external support for preclinical research?
Outside support becomes a pragmatic choice when internal capabilities no longer match the needs of the program. A company may require specialist assay platforms, omics expertise, patient-derived materials, or disease models that are difficult to establish in-house. Independent replication can also strengthen confidence in important findings. External teams may help resolve technical bottlenecks, expand laboratory capacity, or maintain progress when staffing, infrastructure, development timelines, and funding constraints limit what the internal group can deliver.
External link placement
As a program approaches clinical development, the evidence package must address both scientific questions and regulatory expectations. The FDA explains how laboratory and animal studies support safety assessment before human trials in its overview of preclinical research.
References
- The service-based bioeconomy. Nature Biotechnology 32, 597 (2014). Published July 8, 2014.